These data concur with a recent phase Ib/II clinical study of lenvatinib, a multikinase inhibitor with potent activity against RET, in patients with ER+ advanced breast cancer, which showed efficacy after progression on prior endocrine therapy with or without CDK4/6 inhibitor therapy (56). This evidence concerns the gene CDK4 and breast cancer.